FibroBiologics financials
$1.31−3.68%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$4.0M | -$5.1M | -$2.6M | -$5.0M | -$4.5M | -$4.5M | -$3.7M | -$3.4M | -$3.2M | -$3.5M |
| Net income | -$4.1M | -$5.0M | -$3.2M | -$5.8M | -$4.7M | -$5.0M | -$3.1M | -$500.0K | $898.0K | -$8.5M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.66 | $-1.33 | $-0.49 | $-2.60 | $-2.41 | $-2.71 | $-1.82 | $-0.20 | $0.60 | $-5.40 |
| EBITDA | -$4.0M | -$5.0M | -$1.9M | -$5.0M | -$4.4M | -$4.5M | -$3.2M | -$3.3M | -$3.2M | -$3.4M |
| Operating cash flow | -$3.3M | -$4.4M | -$3.2M | -$4.0M | -$4.0M | -$5.3M | -$3.1M | -$2.6M | -$1.9M | -$4.3M |
| Free cash flow | -$3.3M | -$4.4M | -$3.2M | -$4.0M | -$4.2M | -$5.3M | -$3.2M | -$2.6M | -$2.0M | -$4.3M |
| Diluted shares | 6.3M | 3.8M | 6.6M | 2.2M | 1.9M | 1.8M | 1.7M | 1.7M | 1.6M | 1.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.5M | $1.5M | $4.9M | $4.9M | $8.8M | $8.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $246.0K | $0.00 | $4.6M | $8.1M | $5.8M |
| Total assets | $7.9M | $5.9M | $9.6M | $8.7M | $13.9M | $11.4M |
| Total liabilities | $3.3M | $3.3M | $3.5M | $8.6M | $13.0M | $9.1M |
| Shareholders' equity | $4.6M | $2.6M | $6.2M | $125.0K | $860.0K | $2.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology